

# ENCYCLOPEDIA OF SEPARATION SCIENCE

Access for a limited period to an on-line version of the Encyclopedia of Separation Science is included in the purchase price of the print edition.

This on-line version has been uniquely and persistently identified by the Digital Object Identifier (DOI)

10.1006/rwss.2000

*By following the link*

<http://dx.doi.org/10.1006/rwss.2000>

from any Web Browser, buyers of the Encyclopedia of Separation Science will find instructions on how to register for access.

If you have any problems with accessing the on-line version, e-mail:  
[idealreferenceworks@harcourt.com](mailto:idealreferenceworks@harcourt.com)

This book is printed on acid-free paper.

Copyright © 2000 by ACADEMIC PRESS

The following articles are US Government works in the public domain and not subject to copyright:

III/FOOD TECHNOLOGY/Supercritical Fluid Chromatography  
III/FORENSIC SCIENCES/Liquid Chromatography

III/INSECTICIDES/Gas Chromatography  
Crown Copyright 1999

III/MECHANICAL TECHNIQUES: PARTICLE SIZE SEPARATION  
Copyright © 1999 Minister of Natural Resources, Canada

II/CENTRIFUGATION/Large-Scale Centrifugation  
Copyright © 2000 Minister of Public Works and Government Services, Canada

III/AIR LIQUEFACTION: DISTILLATION  
Copyright © 2000 Air Products and Chemicals, Inc

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher.



Academic Press  
A Harcourt Science and Technology Company  
Harcourt Place, 32 Jamestown Road, London NW1 7BY, UK  
<http://www.academicpress.com>

Academic Press  
A Harcourt Science and Technology Company  
525 B Street, Suite 1900, San Diego, California 92101-4495, USA  
<http://www.academicpress.com>

ISBN 0-12-226770-2

Library of Congress Catalog Number: 99-61531

A catalogue record for this book is available from the British Library

Access for a limited period to an on-line version of the Encyclopedia of Separation Science is included in the purchase price of the print edition.

This on-line version has been uniquely and persistently identified by the Digital Object Identifier (DOI)

10.1006/rwss.2000

By following the link

<http://dx.doi.org/10.1006/rwss.2000>

from any Web Browser, buyers of the Encyclopedia of Separation Science will find instructions on how to register for access.

If you have any problems with accessing the on-line version, e-mail:  
[idealreferenceworks@harcourt.com](mailto:idealreferenceworks@harcourt.com)

Typeset by Macmillan India Limited, Bangalore, India  
Printed and bound in Great Britain by The Bath Press, Bath, Somerset, UK  
00 01 02 03 04 05 BP 9 8 7 6 5 4 3 2 1

## Editorial Advisory Board

**Richard W. Baker**

Membrane Technology & Research Inc (MTR)  
1360 Willow Road, Suite 103  
Menlo Park  
CA 94025, USA

**Kenneth L. Busch**

Kennesaw State University  
Office of Sponsored Programs  
1000 Chastain Road  
Kennesaw  
GA 30144, USA

**Howard A. Chase**

University of Cambridge  
Department of Chemical Engineering  
Pembroke Street  
Cambridge CB2 3RA, UK

**Jan Cilliers**

University of Science and Technology in Manchester  
Department of Chemical Engineering  
PO Box 880  
Manchester M60 1QD, UK

**Alan Dyer**

University of Salford  
School of Sciences, Cockcroft Building  
Salford M5 4WT, UK

**Heinz Engelhardt**

Universität des Saarlandes  
Instrumentelle Analytik/Umweltanalytik  
Postfach 15 11 50  
66041 Saarbruecken, Germany

**William F. Furter**

Royal Military College of Canada  
Department of Chemical Engineering  
Kingston  
Ontario K7K 5L0, Canada

**Josef Janca**

Université de La Rochelle  
Pole Sciences et Technologie  
Equipe de Physico-Chimie Macromoleculaire  
Avenue Michel Crepeau - 17042 La Rochelle, France

**Walt Jennings**

J&W Scientific Incorporated  
91 Blue Ravine Road  
Folsom CA 95630, USA

**Kenneth Jones**

Affinity Chromatography Limited  
Freeport  
Ballsalla  
Isle of Man, UK

**Chris Lowe**

University of Cambridge  
Institute of Biotechnology  
Tennis Court Road  
Cambridge, UK

**David Perrett**

St Bartholomew's and the Royal London School  
of Medicine and Dentistry  
St Bartholomew's Hospital, Department of Medicine  
West Smithfield  
London EC1A 7BE, UK

**Douglas E. Raynie**

The Procter and Gamble Company  
Miami Valley Laboratories  
PO Box 538707  
Cincinnati  
OH 45253-8707, USA

**Peter Schoenmakers**

Shell Research and Technology Centre Amsterdam  
(SRTCA) and University of Amsterdam  
Postbus 38000  
1030 BN Amsterdam, The Netherlands

**Darrell N. Taulbee**

University of Kentucky-Center for Applied Energy  
Research (UK-CAER)  
2540 Research Park Drive  
Lexington  
KY 40511, USA

**Gerda M. van Rosmalen**

Delft University of Technology  
Laboratory for Process Equipment  
Leeghwaterstraat 44  
2628 CA Delft, The Netherlands

**Edward Woodburn<sup>†</sup>**

University of Science and Technology in Manchester  
Department of Chemical Engineering  
PO Box 880  
Manchester M60 1QD, UK

<sup>†</sup>deceased

## Crystallization

W. Beckmann and U. Budde, Schering AG,  
Berlin, Germany

Copyright © 2000 Academic Press

Two decades ago, crystallization was called both an art and a science. However, the field is improving quickly. The crystallization of pharmaceuticals is still sometimes regarded an art and rather a mystery. However, crystallization processes are widely used throughout the production processes of the active ingredient of a drug product, and a lot of knowledge is nowadays available.

For the crystallization of drug substances several aspects have to be considered, as the crystallization process is the last step in the chemical manufacture of pharmaceuticals. The crystallization determines a number of important properties of the drug substance, namely the purity and residual solvent content, the polymorphic form, crystal size and size distribution, and it affects downstream processes such as drying, ease of comminution and formulation of the final drug product.

The crystallization of all drug intermediates have the same goals and follows the same procedures as for other organic substances and thus will not be discussed here separately.

### General Considerations for the Development of the Crystallization Process

In general, the demands on the crystallization of a drug substance differ according to the final use, e.g. if the product is used in oral dosage forms, in ointments or in liquid formulations. However, for the sake of simplicity, it is assumed here that the crystallized drug substance is to be used in an oral dosage form.

Figure 1 shows a typical crystallization process of a drug substance and the downstream processes up to the formulation of the drug product. The crystallization and the properties of the product have a great influence on all the following steps.

#### Impurities

**Foreign and related compounds** The requirements on the purity of a drug substance are strict; guidelines require a purity of typically >98%. Individual impurities with a known structure have to be below 0.5% and unidentified impurities have to be below 0.1 or

0.05%. In addition, the toxicological effect of all impurities must have been assessed in the first toxicological tests, i.e. no new impurity is allowed that has not been present in the batch used for toxicological experiments.

The purification of a drug substance via crystallization cannot be predicted easily. While foreign impurities can mostly be easily reduced, related substances like impurities stemming from side reactions in the synthesis behave in an unpredictable way. In general, the purification via crystallization will decrease with an increase in the yield, especially if the yields are >90–95%.

**Residual solvent content** Beside obvious solvent properties such as a certain solubility for the drug substance and an appropriate purification to yield ratio, the choice of the solvent for the crystallization of a drug substance is governed by the permissible limitations placed on the residual solvent content of the drug substance. All typical solvents have been classified according to their toxicity and tolerated daily uptakes of a solvent have been established, that are not to be exceeded by the drug product.

Three classes of solvents are distinguished: (i) those that should be avoided; (ii) those that have a limit to their daily uptake; and (iii) those for which no limits have been set up so far. Examples are benzene and dichloroethane for class 1, methanol and dichloromethane for class 2 and ethanol, ethyl acetate and acetone for class 3. In addition, good manufacturing practice (GMP) requires the manufacturer to limit the residual solvent to the lowest content possible.

Dissolution in solvent for crystallization

↓  
Filtering, typically 1–10 μm

↓  
Crystallization

↓  
Solid-liquid separation

↓  
Drying

↓  
Homogenization

↓  
Comminution

↓  
Formulation

Figure 1 Typical crystallization and downstream processes up to formulation.

**Table 1** Productivity, yield and development prerequisites for the separation of isomers via crystallization, enzymatic resolution and chromatography

Parameter	Crystallization	Enzymatic resolution	Chromatography
Productivity	High	Low	Medium
Selectivity	Varies	High	Very high
Prerequisite	High	High	Low
Development time	High	High	Low to medium

Two types of limits for the residual solvent content of a drug are distinguished. Case 1 is a dosage-independent concentration limit and Case 2 is a limit for the total uptake through the drug product, that must not be exceeded by the solvent content of the drug substance and the excipients.

The mechanisms of incorporation of solvent into the crystals can be described as follows:

- The solvent is incorporated into the lattice at fixed positions during the crystallization (solvate formation). In this case, the incorporation cannot be avoided directly. In some cases, a solvent of crystallization is removed or replaced by water.
- The solvent is incorporated into the lattice as three-dimensional inclusions. The formation of inclusions is facilitated by the speed of crystallization, thus, the amount of residual solvent can be decreased by lowering the rate of crystallization. For some systems, the tendency to form three-dimensional inclusions of solvent increases with the crystal size.

If a problem with the residual solvent content of a drug arises, the clear remedy is a change of solvent.

**Separation of isomers** An increasing number of pharmaceutical active ingredients are either isomers or enantiomers. Typically, different isomers of a chemical compound exhibit different biological or

therapeutic activities, with one of the isomers being the carrier of the activity. In some cases, the second isomer can even have an adverse biological activity. In any case, the inactive isomer constitutes an unnecessary load to the body. Thus, a separation of isomers is almost a prerequisite for the production of a drug.

Isomers can be separated by enzymatic resolution, chromatography or crystallization. Table 1 summarizes and compares productivity, yield and development prerequisites of the three separation techniques.

The success (or possibility) of the separation of isomers via crystallization depends on the phase diagram of the two compounds.

Figure 2 shows typical phase diagrams of isomers, i.e. eutectics, solid solutions and partial solubility in the solid state. A separation of isomers in a single step is only feasible for eutectic systems. Systems forming solid solutions have to be purified in multiple steps, as for example in zone refining which is only feasible if the substance is stable in the molten state. For systems exhibiting partial miscibility in the solid state, the separation cannot be better than the partial miscibility concentrations.

In principle, isomers forming eutectics can be separated directly via crystallization. However, without using special techniques, the crystallization can only be carried out until the concentration of the mother liquor has reached the composition of the eutectic mixture. To improve the yield two ways are often pursued:




Figure 2 Typical phase diagrams for isomers: eutectics, complete miscibility in the solid state, and partial miscibility in the solid

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.